最新观点
Insights From Our Experts
Articles
Precision Medicine Meets Precision Patient Support
Posted on 4 月 9, 20194/9/19
In the value-driven healthcare environment, orphan drug manufacturers are becoming increasingly aware that improving adherence requires a new approach to patient understanding and support. Take for example the required lifestyle, nutritional or physical modifications often necessary…
Biosimilar Pricing in Europe
This report titled Biosimilar Pricing in Europe is published by Pricentric, by EVERSANA. It examines the pricing and pricing trends of biosimilar drugs in the US and EU5. It particularly looks at the pricing of Infliximab…
Wearables In Clinical Trials
Pharma Voice Magazine features Sandra Shpilberg from Seeker Health, an EVERSANA company, in their March 2019 issue. The topic is “Wearables in Clinical Trial”. The article discusses how wearables are improving the clinical trial experience for patients…
The Brink of the Biosimilar Revolution
Although biosimilars have not had the immediate uptake in the United States that they have had in Europe, health plans expect these products will become a staple of therapy for some diseases by 2020—if the price…
Medicare Part D: Closing the Coverage Gap
Signed into law on February 9, 2018, the Bipartisan Budget Act (BBA) of 2018 entails significant adjustments to consumer spending under the Medicare Part D prescription drug program. Beginning in 2019, the period of out-of-pocket expenses…
The Radical Implications Of Indication-Specific Pricing
This paper discusses one of the potentially more impactful new dynamics in the pricing of pharmaceuticals—the advent of indication-specific pricing. Our goal is to provide context to this important change, highlight some of the implications about…
Don’t Poke The Bear: The Effect Of Pharmaceutical Pricing On Perception And Future Innovation
Companies like Turing Pharmaceuticals and KV Pharmaceuticals have grabbed headlines recently for their aggressive pricing strategies. Whether these strategies are justified or even successful is not the point. Rather, what is important is the negative public…